Additionally, loss of SETD2 induced hypersensitivity against the DOT1L inhibitor pinometostat (EPZ-5676; currently in phase 1 and 2 clinical trials, see NCT03701295 and NCT03724084 at https://clinicaltrials.gov, accessed on 1 August 2021) in MLL-rearranged AML cells [12]. Here, SETD2 is linked to acute myeloid leukemia.